LY3435151
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 15, 2020
A Study of LY3435151 in Participants With Solid Tumors
(clinicaltrials.gov)
- P1a/1b; N=2; Terminated; Sponsor: Eli Lilly and Company; N=230 ➔ 2; Recruiting ➔ Terminated; Study terminated due to strategic business decision by Eli Lilly and Company.
Clinical • Enrollment change • Trial termination • Breast Cancer • Cervical Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Head and Neck Cancer • Hepatocellular Cancer • Leiomyosarcoma • Liver Cancer • Oncology • Ovarian Cancer • Sarcoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • Uterine Leiomyoma • Women's Health
March 03, 2020
A Study of LY3435151 in Participants With Solid Tumors
(clinicaltrials.gov)
- P1a/1b; N=230; Recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Jan 2023 ➔ Jun 2020; Trial primary completion date: Jan 2023 ➔ Jun 2020
Clinical • Trial completion date • Trial primary completion date
November 09, 2019
A Study of LY3435151 in Participants With Solid Tumors
(clinicaltrials.gov)
- P1a/1b; N=230; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
1 to 3
Of
3
Go to page
1